[go: up one dir, main page]

AU2001273040A1 - Factor xa inhibitors - Google Patents

Factor xa inhibitors

Info

Publication number
AU2001273040A1
AU2001273040A1 AU2001273040A AU7304001A AU2001273040A1 AU 2001273040 A1 AU2001273040 A1 AU 2001273040A1 AU 2001273040 A AU2001273040 A AU 2001273040A AU 7304001 A AU7304001 A AU 7304001A AU 2001273040 A1 AU2001273040 A1 AU 2001273040A1
Authority
AU
Australia
Prior art keywords
inhibitors
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273040A
Inventor
Patrick Y. Lam
Yunlong Li
Donald J. P. Pinto
Mimi L. Quan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001273040A1 publication Critical patent/AU2001273040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001273040A 2000-06-27 2001-06-27 Factor xa inhibitors Abandoned AU2001273040A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21475800P 2000-06-27 2000-06-27
US60214758 2000-06-27
US24612400P 2000-11-06 2000-11-06
US60246124 2000-11-06
PCT/US2001/020538 WO2002000651A2 (en) 2000-06-27 2001-06-27 Factor xa inhibitors

Publications (1)

Publication Number Publication Date
AU2001273040A1 true AU2001273040A1 (en) 2002-01-08

Family

ID=26909329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273040A Abandoned AU2001273040A1 (en) 2000-06-27 2001-06-27 Factor xa inhibitors

Country Status (2)

Country Link
AU (1) AU2001273040A1 (en)
WO (1) WO2002000651A2 (en)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
ES2347544T3 (en) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv INHIBITORS OF HISTONA-DESACETILASAS.
MXPA04008796A (en) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitors of histone deacetylase.
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
ATE323702T1 (en) 2002-08-06 2006-05-15 Astrazeneca Ab CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
EA010380B1 (en) 2002-08-08 2008-08-29 Амген Инк. Vanilloid receptor ligands
WO2004050636A2 (en) * 2002-12-04 2004-06-17 Aventis Pharma Deutschland Gmbh IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
EP1479674A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Imidiazole-derivatives as factor xa inhibitors
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
AU2003292218A1 (en) * 2002-12-23 2004-07-14 Sanofi-Aventis Deutschland Gmbh PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479680A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479679A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazole-derivatives as factor Xa inhibitors
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL1651612T3 (en) 2003-07-22 2012-09-28 Astex Therapeutics Ltd 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2556239A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
JP4883296B2 (en) 2004-03-05 2012-02-22 日産化学工業株式会社 Isoxazoline-substituted benzamide compounds and pest control agents
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2006002099A2 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
SE0401653D0 (en) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (en) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Methods for treating hepatitis c.
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
MX2007001120A (en) 2004-07-28 2007-03-15 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase.
CN101213194A (en) 2004-08-03 2008-07-02 惠氏公司 Indazoles useful in treating cardiovascular diseases
ATE545644T1 (en) 2004-09-24 2012-03-15 Astrazeneca Ab BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PRODUCTION THEREOF AND USES THEREOF I
EP1817292B1 (en) 2004-11-16 2015-04-08 Janssen Pharmaceutica NV Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
DE102004058062A1 (en) * 2004-12-02 2006-06-08 Bayer Healthcare Ag Cyclic iminocarbamates and their use
AR051984A1 (en) 2004-12-08 2007-02-21 Bristol Myers Squibb Co HETEROCICLICAL COMPOUNDS AS INHIBITORS OF THE FACTOR VIIA
DE102004059219A1 (en) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Pyrazine dicarboxylic acid amides and their use
DE102004061751A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidine-substituted pyrazolines
DE102004061747A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Thiophene-substituted pyrazolines
AU2005321091B2 (en) 2004-12-30 2012-04-12 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
KR101346886B1 (en) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 Pharmaceutical compounds
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
KR101364762B1 (en) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. Compounds for the treatment of proliferative disorders
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
DE102005042583A1 (en) * 2005-09-08 2007-03-15 Bayer Healthcare Ag Iminooxazolidine derivatives and their use
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
WO2007073298A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
BRPI0620464A2 (en) 2005-12-23 2011-11-16 Astrazeneca Ab compound, pharmaceutical composition, use of a compound, and method for treating a disease
WO2007073296A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
ES2395392T3 (en) 2005-12-29 2013-02-12 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
JP5474354B2 (en) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
CN101370790B (en) 2006-01-19 2015-10-21 詹森药业有限公司 As pyridine and the pyrimidine derivatives of NSC 630176
NZ570014A (en) 2006-02-03 2011-04-29 Bionomics Ltd Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
JP5227311B2 (en) 2006-05-05 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Factor Xa inhibitor
JP5523829B2 (en) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド Compound drug
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
EP2091944B1 (en) 2006-11-17 2011-05-18 Pfizer Inc. Substituted bicyclocarboxyamide compounds
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CA2691849A1 (en) 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
MX2010005298A (en) 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Carboxamide, sulfonamide and amine compounds for metabolic disorders.
JP5650540B2 (en) 2007-12-12 2015-01-07 ライジェル ファーマシューティカルズ， インコーポレイテッド Carboxamide, sulfonamide, and amine compounds for metabolic disorders
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
KR101662333B1 (en) 2008-04-23 2016-10-04 리겔 파마슈티칼스, 인크. Carboxamide compounds for the treatment of metabolic disorders
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
JP5640005B2 (en) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Imidazosylpyridine compounds as HDAC and / or CDK inhibitors
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CN102123987A (en) 2008-07-28 2011-07-13 吉里德科学公司 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
AU2010256360A1 (en) 2009-06-05 2012-01-12 Astrazeneca Ab Aminopyrrolidinone derivatives and uses thereof
WO2010144378A2 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
JP2013501064A (en) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
CN102762550B (en) 2009-12-17 2015-04-01 米伦纽姆医药公司 Salts and crystalline forms of a factor xa inhibitor
NZ718622A (en) 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
MX2013004193A (en) 2010-11-11 2013-06-05 Sanofi Sa Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives.
CN103596947A (en) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
JP6165733B2 (en) 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
KR101093102B1 (en) 2011-10-04 2011-12-13 (주)목우연구소 Phenylisoxazolin-based compound having herbicidal activity and use thereof
ES2816060T3 (en) 2012-02-29 2021-03-31 Chemocentryx Inc Aza-aryl 1H-pyrazol-1-yl-benzenesulfonamides as CCR antagonists (9)
EP2871179A4 (en) * 2012-07-03 2016-03-16 Ono Pharmaceutical Co Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
JP6423372B2 (en) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
CN105209039B (en) 2013-03-15 2018-06-22 百时美施贵宝公司 LXR conditioning agents
BR112015022340A2 (en) 2013-03-15 2017-07-18 Verseon Corp method for treating or preventing a kallikrein-related disease or disorder in a subject, compound, and pharmaceutical composition
CA2929858C (en) 2013-11-22 2022-03-29 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds
NZ724250A (en) 2014-03-07 2022-02-25 Biocryst Pharm Inc Human plasma kallikrein inhibitors
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2947002C (en) 2014-06-03 2023-01-03 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
ES2693052T3 (en) 2014-09-15 2018-12-07 Idorsia Pharmaceuticals Ltd Triazole compounds as blockers of the T-type calcium channels
KR20170048410A (en) 2014-09-17 2017-05-08 베르선 코포레이션 Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
IL292655B2 (en) 2014-10-06 2024-03-01 Chemocentryx Inc Ccr9 chemokine receptor inhibitor for use in a method of treating or reducing the development of inflammatory bowel disease
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105477A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MX2017011000A (en) 2015-02-27 2017-10-20 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors.
RU2687245C1 (en) 2015-06-23 2019-05-08 Киссеи Фармасьютикал Ко., Лтд. Pyrazole derivative or its pharmaceutically acceptable salt
CA2993450C (en) 2015-07-24 2023-10-24 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
DK3344248T3 (en) 2015-09-02 2022-06-20 Trevena Inc 6-LINKED AZA HETEROCYCLIC GROUP CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS AND PROCEDURES FOR USE AND MANUFACTURE
JP6929276B2 (en) 2015-10-06 2021-09-01 プロテオステイシス セラピューティクス，インコーポレイテッド Compounds, pharmaceutically acceptable salts or stereoisomers thereof and pharmaceutical compositions
BR112018070747B1 (en) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc SILICONE ATOMS CONTAINING IVACAFTOR ANALOGS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
ES2954658T3 (en) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compounds, compositions and methods for increasing CFTR activity
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
PL3554490T3 (en) 2016-12-16 2022-05-30 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
JP6972144B2 (en) 2017-02-06 2021-11-24 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd A novel method for synthesizing 1-aryl-1-trifluoromethylcyclopropane
WO2018152286A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN110520129A (en) 2017-02-17 2019-11-29 特维娜有限公司 Delta opiate receptor modulating compound and its use and preparation method containing 5 yuan of aza heterocycles
ES2946917T3 (en) 2017-07-21 2023-07-27 Antabio Sas Chemical compounds
KR20200143376A (en) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. Substituted imidazopyridines and uses thereof as plasma kallikrein inhibitors
EP3587416A1 (en) 2018-06-29 2020-01-01 Institut Univ. de Ciència i Tecnologia, S.A. 2-oxopiperidin-3-yl derivatives and use thereof
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR102135106B1 (en) * 2018-12-11 2020-07-17 재단법인 경기도경제과학진흥원 Antiviral Composition for Middle East Respiratory Syndrome Coronavirus
WO2021055621A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Plasma kallikrein inhibitors and uses thereof
CN114667289A (en) 2019-09-18 2022-06-24 武田药品工业有限公司 Heteroaryl plasma kallikrein inhibitors
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
CN115210229A (en) 2020-01-03 2022-10-18 博格有限责任公司 Polycyclic amides as UBE2K modulators for the treatment of cancer
US20240109865A1 (en) 2020-12-30 2024-04-04 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
WO2022265993A1 (en) 2021-06-14 2022-12-22 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
AR127064A1 (en) 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd PRODRUGS OF PYRROLIDONE DERIVATIVES AS A GLUCOKINASE ACTIVATOR
EP4356909A1 (en) 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502655A (en) * 1995-12-21 2001-02-27 デュポン ファーマシューティカルズ カンパニー Isoxazoline, isothiazoline and pyrazoline which are factor Xa inhibitors

Also Published As

Publication number Publication date
WO2002000651A3 (en) 2002-06-13
WO2002000651A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2001273040A1 (en) Factor xa inhibitors
AU2002350217A1 (en) Glycinamides as factor xa inhibitors
AU2001258771A1 (en) -secretase inhibitors
HRP20040453A2 (en) Indole-2-carboxamides as factor xa inhibitors
AU6762400A (en) Inhibitors of factor xa
AU5723500A (en) Inhibitors of factor xa
ZA200306490B (en) Inhibitors of factor Xa.
AU5158100A (en) Inhibitors of factor xa
AU5283900A (en) Inhibitors of factor xa
AU3857300A (en) Inhibitors of factor xa
AU2002220241A1 (en) Parb inhibitors
AU2002365896A1 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
AU5284000A (en) Inhibitors of factor xa
AU2001293297A1 (en) Phyisological profiling
AU2001244847A1 (en) Water-retaining structure
AU2001249397A1 (en) Oxindole inhibitors of factor xa
AU2001294557A1 (en) Thrombin inhibitors
IL162454A0 (en) Pyrrolidine-2-ones as factor xa inhibitors
AU2001294824A1 (en) Piperazine based inhibitors of factor xa
AU2001281843A1 (en) Dipeptide inhibitors for the blood-clotting factor Xa
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
AU2002222933A1 (en) Inhibitors of factor xa
AU2003296393A1 (en) Factor xa inhibitors
AU2002348501A1 (en) Factor xa inhibitor
AU2001283340A1 (en) Factor viia inhibitors